Cystic Fibrosis Foundation

Active

Website LinkedIn X

Updated: Apr 2, 2026 ·

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Aug 1, 2025	SNIPR Biome	$41.0M Series B	—	AbbVie Ventures, Agent Capital, MRL Ventures Fund, Wellington Partners, Lundbeckfonden BioCapital, North East Family Office, The Federal Agency for Disruptive Innovation
Jul 16, 2025	Prime Medicine	$24.0M Other Equity	Michael Boyle	—
Nov 18, 2024	ReCode Therapeutics	$15.0M Other Equity	Cystic Fibrosis Foundation	—
Apr 3, 2024	Splisense	$8.5M Other Equity	Cystic Fibrosis Foundation	—
Mar 1, 2024	Sionna Therapeutics	$180.0M Series C	Edd Fleming	Atlas Venture, OrbiMed, Third Rock Ventures, Perceptive Advisors, Q Healthcare Holdings, RA Capital Management, Michael Cloonan, TPG, T. Rowe Price Associates, Viking Global Investors
Jan 25, 2024	Prime Medicine	$15.0M Other Equity	Cystic Fibrosis Foundation	—
Jan 5, 2024	Clarametyx Biosciences	$33.0M Series A	Bill Baumel	1776, C Bio Investors, JobsOhio Growth Capital, Nationwide Children, Rev1 Ventures
Nov 1, 2023	ViaNautis	$25.0M Series A	4BIO Capital, Lucy Edwardes Jones, Steven Biesmans	Business Growth Fund, Parkwalk Advisors, Eli Lilly and Company, Meltwind, O2H, Origin Capital
Sep 26, 2023	Arcturus Therapeutics	$9.0M Other Equity	Clancy JP	—
Jan 10, 2023	ReCode Therapeutics	$210.0M Series B	Cystic Fibrosis Foundation	—
Dec 1, 2022	Pulmocide	$52.0M Series C	—	Adjuvant Capital, Asahi Kasei Pharma, F-Prime Capital, Sabine Dandiguian, Johnson & Johnson Innovation, Longwood Fund, Pictet Alternative Advisors, SR One, SV Health Investors, Vivo Capital
Jun 1, 2022	Carbon Biosciences	$38.0M Series A	Agent Capital	Hiromichi Kimura, Astellas Venture Management, Camford Capital, Martin Mense, David Steinberg, Derek Yoon, University of Tokyo Edge Capital
Apr 1, 2022	Sionna Therapeutics	$110.0M Series B	OrbiMed	Atlas Venture, Third Rock Ventures, Michael Boyle, Q Healthcare Holdings, Joshua Resnick, Lucian Iancovici, T. Rowe Price Associates
Mar 29, 2022	Eloxx	$15.9M Other Equity	Michael Boyle	—
Jan 5, 2022	SalioGen Therapeutics	$115.0M Series B	EPIQ Capital Group, Craig Gordon	Martin Mense, D1 Capital Partners, Fidelity Management & Research Company, PBM Capital, RD Fund, SymBiosis, T. Rowe Price Associates
Dec 29, 2021	EnBiotix	$11.0M Other Equity	Vectura Group	Sanford Biosciences
Dec 6, 2021	Pulmocide	$3.5M Other Equity	Albert Faro	—
May 13, 2021	Splisense	$8.4M Series B	William Skach	—
Jun 16, 2020	4D Molecular Therapeutics	$75.0M Series C	Viking Global Investors	Amzak Health, ArrowMark Partners, Berkeley Catalyst Fund, BVF Partners, Casdin Capital, Chiesi Ventures, Michael Boyle, Longevity Vision Fund, Mirae Asset, Octagon Capital, Perceptive Advisors, QUAD Investment Management
Aug 1, 2019	Arcturus Therapeutics	$15.0M Other Equity	Cystic Fibrosis Foundation	—
Sep 19, 2017	4D Molecular Therapeutics	$3.0M Other Equity	Cystic Fibrosis Foundation	—
Jun 8, 2015	Celtaxsys	$45.0M Grant / Series D	Nicole Vitullo	Georgia Research Alliance, Gerry Brunk, Masters Capital Management, Maxim Gorbachev